SCHEMBL8772871

SCHEMBL8772871

NCC(=O)N1CCC[C@H]1C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 9/20 0.56
PREP P48147 1/20 0.56
FAP Q12884 1/20 0.56
DPP8 Q6V1X1 1/20 0.56
DPP9 Q86TI2 1/20 0.56
ACE P12821 2/20 0.45
HTR1A P08908 2/20 0.42
HTR7 P34969 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8772866 1.00 DPP4 (0.56) DPP4PREPFAPDPP8DPP9
Hydrochloric Acid SCHEMBL29548868 0.98 DPP4 (0.54) DPP4PREPFAPDPP8DPP9
Bromide SCHEMBL9464510 0.98 DPP4 (0.54) DPP4PREPFAPDPP8DPP9
Bromide SCHEMBL9464396 0.98 DPP4 (0.54) DPP4PREPFAPDPP8DPP9
Hydrochloric Acid SCHEMBL19692659 0.98 DPP4 (0.54) DPP4PREPFAPDPP8DPP9
SCHEMBL10884099 0.85 DPP4 (0.54) DPP4ACEHTR1AHTR7
SCHEMBL1493753 0.85 DPP4 (0.47) DPP4ACEHTR1AHTR7
Glycyl Proline SCHEMBL155067 0.85 ACE (0.62) DPP4PREPFAPDPP8DPP9
Glycyl Proline SCHEMBL30051559 0.85 ACE (0.62) DPP4PREPFAPDPP8DPP9
Glycyl Proline SCHEMBL155066 0.85 ACE (0.62) DPP4PREPFAPDPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5599791-A BACTERICIDE ACTIVE AGAINST GRAMNEGATIVE AND GRAMPOSITIVE BACTERIA GRUPPO LEPETIT SPA (IT) 1997-02-04 US claimed
WO-1992012172-A9 AMIDES OF ANTIBIOTIC GE 2270 FACTORS 1996-04-04 WO claimed
EP-0565567-B1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS LEPETIT SPA (IT) 1995-01-18 EP claimed
EP-0565567-A1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS. LEPETIT SPA (IT) 1993-10-20 EP claimed
WO-1992012172-A1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS GRUPPO LEPETIT S.P.A. (IT) 1992-07-23 WO claimed
EP-0494078-A1 Amides of antibiotic ge 2270 factors GRUPPO LEPETIT S.p.A. (IT) 1992-07-08 EP claimed
US-20240409531-A1 BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS MERCK SHARP & DOHME LLC (US) 2024-12-12 US disclosed
US-11858924-B2 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides ASTRAZENECA (SE) 2024-01-02 US disclosed
US-20230312550-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2023-10-05 US disclosed
EP-2323981-B1 PROCESS FOR THE PREPARATION OF A MACROCYCLE HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
WO-2009142842-A9 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2010-11-25 WO disclosed
WO-2009142842-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-26 WO disclosed
EP-0800510-A1 HYDROXAMIC ACID-CONTAINING INHIBITORS OF MATRIX METALLOPROTEASES THE PROCTER & GAMBLE COMPANY (US) 1997-10-15 EP disclosed
WO-1996020918-A1 HYDROXAMIC ACID-CONTAINING INHIBITORS OF MATRIX METALLOPROTEASES THE PROCTER & GAMBLE COMPANY (US) 1996-07-11 WO disclosed
WO-1992012172-A9 AMIDES OF ANTIBIOTIC GE 2270 FACTORS 1996-04-04 WO disclosed
EP-0565567-B1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS LEPETIT SPA (IT) 1995-01-18 EP disclosed
EP-0565567-A1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS. LEPETIT SPA (IT) 1993-10-20 EP disclosed
WO-1992012172-A1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS GRUPPO LEPETIT S.P.A. (IT) 1992-07-23 WO disclosed
EP-0494078-A1 Amides of antibiotic ge 2270 factors GRUPPO LEPETIT S.p.A. (IT) 1992-07-08 EP disclosed
US-4558034-A Inhibitors of bacterial collagenase THE BOARD OF TRUSTEES OF THE UNIVERSITY OF KENTUCKY (US) 1985-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409531-A1 BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS NFATC1, ACIN1, GZMB DPP4 3450/4885PREP 925/4885FAP 4628/4885
US-20230312550-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES FAP, PREP, CTRL DPP4 39/4885PREP 2/4885FAP 1/4885
US-11858924-B2 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides FAP, PREP, CTRL DPP4 39/4885PREP 2/4885FAP 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.